collection
MENU ▼
Read by QxMD icon Read
search

MMCBreast Collection

shared collection
187 papers 100 to 500 followers
https://www.readbyqxmd.com/read/28097781/an-analysis-of-oncotype-dx-recurrence-scores-and-clinicopathologic-characteristics-in-invasive-lobular-breast-cancer
#1
Jesse L Felts, Junjia Zhu, Bing Han, Stanley J Smith, Cristina I Truica
The Oncotype DX breast cancer assay (Genomic Health, Redwood City, CA) is increasingly being used to guide treatment decisions for patients with early stage, hormone-positive, Her-2-negative breast cancer. The utility of the Oncotype DX in decision making for treatment of invasive lobular carcinoma (ILC) has not been investigated as the results reported by Genomic Health are largely in a population with invasive ductal carcinoma (IDC). The authors hypothesized that the Oncotype DX recurrence score (RS) distribution for ILC is different than that for IDC...
January 18, 2017: Breast Journal
https://www.readbyqxmd.com/read/28099081/controversies-in-the-treatment-of-ductal-carcinoma-in-situ
#2
Andrea V Barrio, Kimberly J Van Zee
Ductal carcinoma in situ (DCIS) accounts for 20% of all newly diagnosed breast cancers. Mastectomy was once the gold standard for the treatment of DCIS; however, breast-conserving surgery (BCS) has been adopted as the treatment of choice for patients with small, screen-detected lesions. Both adjuvant radiation and hormonal therapy following BCS have been demonstrated in randomized trials to reduce the risk of both invasive and DCIS recurrence, but neither affects survival. With the variety of surgical and adjuvant treatment options available, there has been great interest in tailoring the treatment to the individual, with the goal of optimizing the balance of risks and benefits according to the values and priorities of the woman herself...
January 14, 2017: Annual Review of Medicine
https://www.readbyqxmd.com/read/28089627/the-relationship-between-tamoxifen-associated-nonalcoholic-fatty-liver-disease-and-the-prognosis-of-patients-with-early-stage-breast-cancer
#3
Meiying Yan, Jingxuan Wang, Qijia Xuan, Tieying Dong, Juan He, Qingyuan Zhang
PURPOSE: To investigate the relationship between tamoxifen-associated nonalcoholic fatty liver disease (NAFLD) and survival outcomes in patients with breast cancer. METHODS: Patients with early-stage invasive breast cancer after curative resection from January 2009 to June 2011 were selected. A total of 646 patients who were treated with tamoxifen were included. Patients diagnosed with NAFLD on ultrasonography were classified into the NAFLD and non-NAFLD groups...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28087099/prognostic-and-predictive-indicators-in-early-stage-breast-cancer-and-the-role-of-genomic-profiling-focus-on-the-oncotype-dx-%C3%A2-breast-recurrence-score-assay
#4
E Curtit, L Mansi, Y Maisonnette-Escot, J-L Sautière, X Pivot
Although useful prognostic and predictive insights can be gained from patient and tumour characteristics in early-stage breast cancer, it is not always straightforward to predict the likely risk of recurrence for each individual patient following breast surgery. One of the most difficult challenges faced by clinicians is identifying patients who may benefit most from adjuvant chemotherapy, and distinguishing these cases from those where endocrine therapy may be sufficient for cure. Genomic tests such as the Oncotype DX(®) Breast Recurrence Score(®) Assay have been developed to provide a robust and clinically validated assessment of a patient's individual tumour signature...
December 14, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27807808/predictive-factors-of-pathologic-complete-response-of-her2-positive-breast-cancer-after-preoperative-chemotherapy-with-trastuzumab-development-of-a-specific-predictor-and-study-of-its-utilities-using-decision-curve-analysis
#5
Clémentine Jankowski, S Guiu, M Cortet, C Charon-Barra, I Desmoulins, V Lorgis, L Arnould, P Fumoleau, B Coudert, R Rouzier, C Coutant, F Reyal
PURPOSE: The aim of this study was to assess the Institut Gustave Roussy/M.D. Anderson Cancer Center (IGR/MDACC) nomogram in predicting pathologic complete response (pCR) to preoperative chemotherapy in a cohort of human epidermal growth factor receptor 2 (HER2)-positive tumors treated with preoperative chemotherapy with trastuzumab. We then combine clinical and pathological variables associated with pCR into a new nomogram specific to HER2-positive tumors treated by preoperative chemotherapy with trastuzumab...
January 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28054190/has-the-time-come-to-stop-surgical-staging-of-the-axilla-for-all-women-age-70%C3%A2-years-or-older-with-hormone-receptor-positive-breast-cancer
#6
EDITORIAL
Judy C Boughey, Bruce G Haffty, Elizabeth B Habermann, Tanya L Hoskin, Matthew P Goetz
No abstract text is available yet for this article.
January 4, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28052186/axillary-treatment-for-operable-primary-breast-cancer
#7
REVIEW
Nathan Bromham, Mia Schmidt-Hansen, Margaret Astin, Elise Hasler, Malcolm W Reed
BACKGROUND: Axillary surgery is an established part of the management of primary breast cancer. It provides staging information to guide adjuvant therapy and potentially local control of axillary disease. Several alternative approaches to axillary surgery are available, most of which aim to spare a proportion of women the morbidity of complete axillary dissection. OBJECTIVES: To assess the benefits and harms of alternative approaches to axillary surgery (including omitting such surgery altogether) in terms of overall survival; local, regional and distant recurrences; and adverse events...
January 4, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28064072/long-term-outcome-of-breast-cancer-patients-with-pathologic-n3a-lymph-node-stage
#8
Antonino Grassadonia, Patrizia Vici, Teresa Gamucci, Luca Moscetti, Laura Pizzuti, Lucia Mentuccia, Laura Iezzi, Maria Teresa Scognamiglio, Marinella Zilli, Jamara Giampietro, Vincenzo Graziano, Clara Natoli, Nicola Tinari
PURPOSE: To evaluate factors influencing the long-term outcome of patients presenting with 10 or more metastatic axillary lymph nodes (pN3a) after surgery for primary breast cancer. METHOD: Between January 1990 and December 2015, a total of 130 patients with pN3a breast cancer at surgery were identified in our Institutions and included in the study. Twenty-nine of them (22.3%) received neoadjuvant chemotherapy. The Multivariate Cox proportional hazards model was used to determine independent prognostic factors associated with DFS and OS...
January 5, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28058560/intraoperative-margin-management-in-breast-conserving-surgery-a-systematic-review-of-the-literature
#9
Richard J Gray, Barbara A Pockaj, Erin Garvey, Sarah Blair
BACKGROUND: Breast surgeons have a wide variety of intraoperative techniques available to help achieve low rates for positive margins of excision, with variable levels of evidence. METHODS: A systematic review of the medical literature from 1995 to July 2016 was conducted, with 434 abstracts identified and evaluated. The analysis included 106 papers focused on intraoperative management of breast cancer margins and contained actionable data. RESULTS: Ultrasound-guided lumpectomy for palpable tumors, as an alternative to palpation guidance, can lower positive margin rates, but the effect when used as an alternative to wire localization (WL) for nonpalpable tumors is less certain...
January 5, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28062931/fewer-reoperations-after-lumpectomy-for-breast-cancer-with-neoadjuvant-rather-than-adjuvant-chemotherapy-a-report-from-the-national-cancer-database
#10
Jeffrey Landercasper, Barbara Bennie, Benjamin M Parsons, Leah L Dietrich, Caprice C Greenberg, Lee G Wilke, Jared H Linebarger
BACKGROUND: Reoperations occur frequently after initial lumpectomy for breast cancer. The authors hypothesized that the receipt of neoadjuvant chemotherapy (NAC) is associated with fewer reoperations. METHODS: The association between timing of chemotherapy and reoperation rates (ROR) after lumpectomy was investigated for patients with stages 1-3 breast cancer in the National Cancer Database (NCDB) from 2010 to 2013 by multivariable logistic regression modeling. Then propensity score-matching was performed...
January 6, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28054348/the-effect-of-surgery-type-on-survival-and-recurrence-in-very-young-women-with-breast-cancer
#11
May Lynn Quan, Lawrence Frank Paszat, Kimberly A Fernandes, Rinku Sutradhar, David R McCready, Eileen Rakovitch, Ellen Warner, Frances C Wright, Nicole Hodgson, Muriel Brackstone, Nancy N Baxter
BACKGROUND: The impact of surgical treatment on outcomes in breast cacner in very young women remains unclear. We sought to determine the effect of surgery type on risk of recurrence and survival in a population-based cohort. METHODS: All women diagnosed with breast cancer aged ≤35 (1994-2003) were identified from the Ontario Cancer Registry. Patient, tumor, and treatment variables, including primary surgery, recurrences, and death were abstracted from chart review...
January 5, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28043088/fulvestrant-for-hormone-sensitive-metastatic-breast-cancer
#12
REVIEW
Clara I Lee, Annabel Goodwin, Nicholas Wilcken
BACKGROUND: Fulvestrant is a selective oestrogen receptor down-regulator (SERD), which by blocking proliferation of breast cancer cells, is an effective endocrine treatment for women with hormone-sensitive advanced breast cancer. The goal of such systemic therapy in this setting is to reduce symptoms, improve quality of life, and increase survival time. OBJECTIVES: To assess the efficacy and safety of fulvestrant for hormone-sensitive locally advanced or metastatic breast cancer in postmenopausal women, as compared to other standard endocrine agents...
January 3, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27998227/optimizing-the-use-of-gene-expression-profiling-in-early-stage-breast-cancer
#13
Hyun-Seok Kim, Christopher B Umbricht, Peter B Illei, Ashley Cimino-Mathews, Soonweng Cho, Nivedita Chowdhury, Maria Cristina Figueroa-Magalhaes, Catherine Pesce, Stacie C Jeter, Charles Mylander, Martin Rosman, Lorraine Tafra, Bradley M Turner, David G Hicks, Tyler A Jensen, Dylan V Miller, Deborah K Armstrong, Roisin M Connolly, John H Fetting, Robert S Miller, Ben Ho Park, Vered Stearns, Kala Visvanathan, Antonio C Wolff, Leslie Cope
Purpose Gene expression profiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor-positive, lymph node-negative breast cancer. We hypothesized that the clinical value of these new tools would be more fully realized when appropriately integrated with high-quality clinicopathologic data. Hence, we developed a model that uses routine pathologic parameters to estimate Oncotype DX recurrence score (ODX RS) and independently tested its ability to predict ODX RS in clinical samples...
December 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28002848/multidisciplinary-approach-to-neoadjuvant-endocrine-therapy-in-breast-cancer-a-comprehensive-review
#14
Tomás Reinert, Susana Ramalho, Rodrigo Gonçalves, Carlos Henrique Barrios, Marcia Silveira Graudenz, José Bines
Breast cancer is the most common type of cancer and the leading cause of cancer-related death among women worldwide. Hormone receptor-positive (HR+) tumors represent the most common form of this disease, with more than 70% of breast cancers expressing these receptors. Response and benefit to neoadjuvant chemotherapy (NCT) varies according to HR expression, with lower responses in luminal tumors as compared with hormone receptor-negative (HR-) and human epidermal growth factor receptor 2-positive (HER2+) tumors...
December 21, 2016: Revista Brasileira de Ginecologia e Obstetrícia
https://www.readbyqxmd.com/read/27939057/advances-in-the-treatment-of-advanced-oestrogen-receptor-positive-breast-cancer
#15
REVIEW
Nicholas C Turner, Patrick Neven, Sibylle Loibl, Fabrice Andre
Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development of resistance to therapy is inevitable in advanced cancer. Major progress has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into major advances in the treatment of advanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve progression-free survival...
December 6, 2016: Lancet
https://www.readbyqxmd.com/read/27993168/mammographic-density-assessed-on-paired-raw-and-processed-digital-images-and-on-paired-screen-film-and-digital-images-across-three-mammography-systems
#16
Anya Burton, Graham Byrnes, Jennifer Stone, Rulla M Tamimi, John Heine, Celine Vachon, Vahit Ozmen, Ana Pereira, Maria Luisa Garmendia, Christopher Scott, John H Hipwell, Caroline Dickens, Joachim Schüz, Mustafa Erkin Aribal, Kimberly Bertrand, Ava Kwong, Graham G Giles, John Hopper, Beatriz Pérez Gómez, Marina Pollán, Soo-Hwang Teo, Shivaani Mariapun, Nur Aishah Mohd Taib, Martín Lajous, Ruy Lopez-Riduara, Megan Rice, Isabelle Romieu, Anath Arzee Flugelman, Giske Ursin, Samera Qureshi, Huiyan Ma, Eunjung Lee, Reza Sirous, Mehri Sirous, Jong Won Lee, Jisun Kim, Dorria Salem, Rasha Kamal, Mikael Hartman, Hui Miao, Kee-Seng Chia, Chisato Nagata, Sudhir Vinayak, Rose Ndumia, Carla H van Gils, Johanna O P Wanders, Beata Peplonska, Agnieszka Bukowska, Steve Allen, Sarah Vinnicombe, Sue Moss, Anna M Chiarelli, Linda Linton, Gertraud Maskarinec, Martin J Yaffe, Norman F Boyd, Isabel Dos-Santos-Silva, Valerie A McCormack
BACKGROUND: Inter-women and intra-women comparisons of mammographic density (MD) are needed in research, clinical and screening applications; however, MD measurements are influenced by mammography modality (screen film/digital) and digital image format (raw/processed). We aimed to examine differences in MD assessed on these image types. METHODS: We obtained 1294 pairs of images saved in both raw and processed formats from Hologic and General Electric (GE) direct digital systems and a Fuji computed radiography (CR) system, and 128 screen-film and processed CR-digital pairs from consecutive screening rounds...
December 19, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27919884/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3
#17
F Cardoso, A Costa, E Senkus, M Aapro, F André, C H Barrios, J Bergh, G Bhattacharyya, L Biganzoli, M J Cardoso, L Carey, D Corneliussen-James, G Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, A Gennari, N Harbeck, C Hudis, B Kaufman, I Krop, M Mayer, H Meijer, S Mertz, S Ohno, O Pagani, E Papadopoulos, F Peccatori, F Pernault-Llorca, M J Piccart, J Y Pierga, H Rugo, L Shockney, G Sledge, S Swain, C Thomssen, A Tutt, D Vorobiof, B Xu, L Norton, E Winer
No abstract text is available yet for this article.
December 5, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27988977/prognostic-factors-for-metachronous-contralateral-breast-cancer-implications-for-management-of-the-contralateral-breast
#18
Schelomo Marmor, Pamela R Portschy, Erin E Burke, Beth A Virnig, Todd M Tuttle
The absolute number of breast cancer survivors who are at risk for metachronous contralateral breast cancer (mCBC) has dramatically increased. The objectives of this study were to identify factors predictive of survival for patients with mCBC and to determine clinicopathological factors predictive of advanced mCBC. Using the Surveillance, Epidemiology, and End Results data base, we identified women, ages 18-80, diagnosed with invasive breast cancer from 1992 to 2010. We excluded patients with bilateral and stage IV primary breast cancer...
December 18, 2016: Breast Journal
https://www.readbyqxmd.com/read/27939569/benign-phyllodes-tumours-of-the-breast-over-treatment-of-margins-a-literature-review
#19
REVIEW
M Shaaban, L Barthelmes
BACKGROUND: Phyllodes tumours form a small group of fibroepithelial breast lesions (2-3%). They are classified as benign, borderline, or malignant. (1). Benign phyllodes tumours are the largest subgroup of phyllodes tumours (50-80%), (2) A margin of 1 cm has been suggested as standard of care for all groups of phyllodes tumours.(3-6) METHODS: We performed a literature review from January 2009 to April 2016 including the non-English literature. We compared studies taking a 1 mm margin, 10 mm margin and studies with focal margin involvement...
November 5, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27933411/society-of-surgical-oncology-breast-disease-working-group-statement-on-prophylactic-risk-reducing-mastectomy
#20
Kelly K Hunt, David M Euhus, Judy C Boughey, Anees B Chagpar, Sheldon M Feldman, Nora M Hansen, Swati A Kulkarni, David R McCready, Eleftherios P Mamounas, Lee G Wilke, Kimberly J Van Zee, Monica Morrow
Over the past several years, there has been an increasing rate of bilateral prophylactic mastectomy (BPM) and contralateral prophylactic mastectomy (CPM) surgeries. Since publication of the 2007 SSO position statement on the use of risk-reducing mastectomy, there have been significant advances in the understanding of breast cancer biology and treatment. The purpose of this manuscript is to review the current literature as a resource to facilitate a shared and informed decision-making process regarding the use of risk-reducing mastectomy...
February 2017: Annals of Surgical Oncology
label_collection
label_collection
6331
1
2
2016-12-11 15:34:07
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"